irs program accomplishments · form 990 part iii · fy2024
What they reported doing
- #1 primary $53KMEETINGS AND EDUCATIONAL SUPPORT ($53,006) - TRAVEL, LODGING, AND BOARDING FOR MSK ATTENDINGS, MSK TECHNICIAN, INTERNS AND SUPPORT FOR SCIENTIFIC MEETINGS.
- #2 $19KFUNDACION NATALI DAFNE FLEXER ($19,000) - SUPPORT CLINIC & MOLECULAR STUDIES OF RETINOBLASTOMA RESEARCH UNDER DIRECT OF DR. GUILLERMO CHANTADA, MD. PHD AND DR. PAULA SCHAIQUEVICH PHD. THIS SUPPORTS RETINOBLASTOMA RESEARCH IN ARGENTINA AND SPAIN INCLUDING SUPPORT FOR LAB PERSONNEL, ATTENDANCE AT MEETINGS, SUPPLIES AND PUBLICATION.
named programs · 5 · from sources
What they call their work
Glaucoma Fellowship Program
Provided 10 years of support for a glaucoma fellowship at Mount Sinai School of Medicine, including funding for teaching activities conducted by the fellow.
Latin American Eye Cancer Symposium
Supported the first Latin American Eye Cancer Symposium in New York, bringing together doctors from Mexico, Argentina, Venezuela, Peru, and Brazil to establish treatment protocols for pediatric eye cancer.
Nursing Education Exchange
Supported exchange programs for nurses from Norway and Memorial Sloan Kettering Cancer Center to promote international collaboration in ophthalmic oncology nursing.
Ocular Prosthesis Development
Funded the development of a computer-based ocular prosthesis with normal pupil response and movement; patent pending.
Retinoblastoma Teaching Guide
Development and distribution of a multilingual illustrated guide for patients, families, and healthcare professionals about retinoblastoma, available in print and online in six languages.
activities · 4 groups
What they do
-
Vision Research Funding 3 activities
- Funding educational initiatives in ophthalmologySupports educational programs including the Macula Society Educational Fund, development of multilingual teaching materials, and sponsorship of scientific meetings to advance knowledge dissemination in ophthalmology.
- Funding ophthalmology researchFunds prospective, retrospective, and randomized medical trials, as well as basic and clinical research in ophthalmology, leading to over 200 peer-reviewed scientific publications. Specific funded research includes intraarterial chemotherapy for retinoblastoma, molecular studies of ocular tumors, and development of diagnostic technologies.
- Funding technology development in ophthalmologyFinances the investigation, development, and application of modern technologies for treating blindness and related conditions, including a computer-based ocular prosthesis with natural pupil response and movement (patent pending) and adaptation of electroretinography for pediatric use under anesthesia.
-
-
Healthcare Education Scholarships and Fellowships 1 activity
- Funding fellowship programs in ophthalmologySupports fellowship training programs, including a ten-year funded glaucoma fellowship at Mount Sinai School of Medicine with support for teaching activities, and international fellowships for physicians and scientists in ophthalmology.
-
-
Medical Research Funding 1 activity
- Funding travel for medical professionals and traineesProvides financial support for travel, lodging, and boarding for physicians, scientists, nurses, technicians, interns, and support staff from Memorial Sloan Kettering and other institutions to attend scientific and medical meetings, including over 100 participants across local, national, and international events.
-
-
Uncategorized 1 activity
- Funding international retinoblastoma research collaborationsProvides grants to support clinical and molecular studies of retinoblastoma in Argentina and Spain, including funding for lab personnel, meeting attendance, supplies, publication, and collaborative exchange with Memorial Sloan Kettering Cancer Center.
-
financials · form 990 · fy2024
revenue
Total revenue$70K
Contributions & grants$34K48%
Program service revenue$00%
Investment income$36K52%
Other revenue$0
expenses
Total expenses$136K
Program expenses96%
Admin / overhead4%
Fundraising0%
Salaries & benefits$0
Grants paid out$130K
Largest expense lineFacilities
balance sheet
Total assets$777K
Cash$119K
Investments$656K
Liabilities$58K
Net assets$719K
Liquid reserves68.5 mo
5 years on record · 2020–2024 · YoY revenue +33.5%
leadership · form 990 part vii · fy2024
Who runs it
board members · 6
- ALLAN ABRAMSON MD — DIRECTOR
- DAVID H ABRAMSON MD — DIRECTOR & PRESIDENT
- HILARY CRUZ-ABRAMS BAMPHRN — DIRECTOR & VP & TREASURER
- JOSEPH GOLD MD — DIRECTOR
- NICHOLAS GRUMBACH MD — DIRECTOR
- ROBIN CRUZ-ABRAMS — DIRECTOR
relationships · 7
Who they work with
- Dr. Abramson Partner — Conducted research on intraarterial chemotherapy for retinoblastoma supported by the Fund.
- Dr. Abramson Partner — Delivers lectures supported by the organization.
- Fundacion Natali Dafne Flexer Partner — Funds retinoblastoma research under the direction of Dr. Guillermo Chantada and Dr. Paula Schaiquevich in Argentina and Spain.
- Macula Society Educational Fund Partner — Funds various educational initiatives in ophthalmology.
- Memorial Sloan Kettering Cancer Center Partner — Collaborates on nursing and researcher exchanges, and provides content for patient education resources.
- Mount Sinai School of Medicine Partner — Partner institution for a decade-long glaucoma fellowship program.
- Sant Joan de Deu Research Foundation Partner — Funds retinoblastoma research under the direction of Dr. Guillermo Chantada in Argentina and Spain.
strategies · 3
How they approach the work
Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.
- Inclusive Knowledge Disseminationmethodology: inclusive_disseminationBy supporting travel to scientific meetings and developing accessible, multilingual educational materials, the organization enhances ophthalmic education because inclusive communication improves understanding among diverse audiences—including patients, families, and professionals—across language and ability barriers.
- Integrated Ophthalmic Advancementmethodology: integrated_academic_supportBy integrating research, teaching, technology, and education—particularly in the areas of eye cancers and retinal diseases—the organization advances ophthalmic knowledge because synergistic support across these domains accelerates innovation and clinical application.
- Targeted Research Funding for Clinical Impactmethodology: research_fundingBy funding high-impact research initiatives such as intraarterial chemotherapy and international retinoblastoma studies, the organization enables advances in ophthalmic treatment because targeted financial support drives clinical innovation and sustained scientific inquiry.